The MHRA has fundamentally transformed how pharmaceutical companies obtain export certificates for human medicines. All applications must now be submitted through the digital platform, with complete elimination of paper-based documentation workflows. This change requires UK-based manufacturers and distributors to transition their administrative processes accordingly.
Three critical developments affect industry operations: first, 100 percent electronic processing streamlines compliance and reduces administrative burden; second, 24/7 system access enables real-time monitoring of application status and expedites export timelines; third, the elimination of paper workflows creates a unified, traceable digital record of all export certifications. Companies should familiarise themselves with the new platform interface and update their internal procedures to align with this mandatory digital transition. These changes maintain existing regulatory safety standards while improving operational efficiency for international pharmaceutical commerce.
Read the full article on GMJ Newsroom.
Was this article helpful?
